Innovent’s IBI351 Receives BTD by the NMPA for the Treatment of Advanced Non-small Cell Lung Cancer
Shots:
- The BTD was received based on the data from the P-I/II clinical trial evaluating the safety, tolerability & efficacy of IB1351 monotx. In patients with advanced solid tumors incl. NSCLC who failed or were intolerant to SoC treatment
- The results from the study demonstrated that 55 patients depicted an ORR of 50.9% & DCR of 92.7% whereas 21 patients treated at 600mg BID depicted an ORR of 61.9% & DCR of 100%. Both mDOR & PFS were not reached
- IB1351 is a KRASG12C inhibitor that targets the GTP/GDP exchange by modifying the cysteine residue of KRASG12C protein. Additionally, the company expects to publish the updated study results at an upcoming medical conference in 2023
Ref: PRNewswire | Image: Innovent
Related News:- Innovent Entered into a Collaboration and License Agreement with LG Chem for Tigulixostat to Treat Gout Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
